Axcynsis Therapeutics

Developer of immunotherapies for cancer treatment

placeSingapore, Singapore, Singapore calendar_todayFounded 2022 groups23 employees language axcynsis.com

Registered entities

Innovation

3 patent families — focus: Chemistry & metallurgy, Human necessities; filing pace active. Cited 55 times.

YearFilings
20241
20253
20262

Social engagement

Social engagement: 1.4K social following, 6 posts in the last 12 months — below the industry typical range.

Investor mix

1 investor on record; lead investors include Trinity Innovation Bioventure Singapore.

Investor typeCountShare
Venture capital1100%

Recent activity

29 May 2026
Event
5th World ADC Summit South Korea
14 Apr 2026
Event
AACR 2026
3 Mar 2026
Event
ADC Asia Congress
Coming soon